ReviewClinical & developmental immunology2012
Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy.
Review in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02717949 (Oral Hepatitis C Treatment for Indolent Lymphoma), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Who cites it
19 citing papers in PubMed, 64 citations in OpenAlex.
- Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (RInternational journal of hematology · 2020Trial
- Primary Cutaneous B-Cell Lymphomas: An Updated Portrait of Classification, Biology, and Clinical Management.European journal of haematology · 2026Review
- Observational
- Blockade of BAFF Reshapes the Hepatic B Cell Receptor Repertoire and Attenuates Autoantibody Production in Cholestatic Liver Disease.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients.Frontiers in immunology · 2020Article
- Article
- Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.Cancer management and research · 2018Review
- Viral Oncology: Molecular Biology and Pathogenesis.Journal of clinical medicine · 2017Review
- [Clinical characteristics and outcome of 216 indolent B cell lymphomas].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Hepatitis C Associated B-cell Non-Hodgkin Lymphoma: Clinical Features and the Role of Antiviral Therapy.Journal of clinical and translational hepatology · 2015Review
- Successful and Safe Long-Term Standard Antiviral Therapy in a Patient with "Explosive" Immune Response in Course of HCV-Related Liver Cirrhosis.International journal of molecular sciences · 2015Article
- The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas.Current treatment options in oncology · 2015Review
- Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity.Hepatology (Baltimore, Md.) · 2015Article
- Non-Hodgkin lymphoma and hepatitis C: where we are and what next?Pathology oncology research : POR · 2015Review
- Benign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus Infection.International journal of preventive medicine · 2014Review
- Secondary cutaneous marginal zone B-cell lymphoma presenting as lipoatrophy in a patient with hepatitis C.Journal of dermatological case reports · 2014Article
- Molecular and cytogenetic characterization of expanded B-cell clones from multiclonal versus monoclonal B-cell chronic lymphoproliferative disorders.Haematologica · 2014Article
- Waldenström macroglobulinemia in hepatitis C: case report and review of the current literature.Case reports in oncological medicine · 2014Article
- Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges.Revista brasileira de hematologia e hemoterapiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkin's lymphomas (NHL) has been demonstrated by epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan, and southern parts of United States. In these countries, together with diffuse large B-cell lymphomas, marginal zone lymphomas are the histotypes most frequently associated with HCV infection; in Italy around 20-30% cases of marginal zone lymphomas are HCV positive. Recently, antiviral treatment with interferon with or without ribavirin has been proved to be effective in the treatment of HCV-positive patients affected by indolent lymphoma, prevalently of marginal zone origin. An increasing number of experiences confirmed the validity of this approach in marginal zone lymphomas and in other indolent NHL subtypes like lymphoplasmacytic lymphoma. Across different studies, overall response rate was approximately 75%. Hematological responses resulted significantly associated with the eradication of the virus. This is the strongest evidence of a causative link between HCV and lymphomas. The aim of this paper is to illustrate the relationship between HCV infection and different subtypes of indolent B-cell lymphomas and to systematically summarize the data from the therapeutic studies that reported the use of antiviral treatment as hematological therapy in patients with HCV-associated indolent lymphomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.